Phase 3 PALOMA-2 trial

I’m excited to share with you that the results from the Phase 3 PALOMA-2 trial of IBRANCE® (palbociclib) have been published in The New England Journal of Medicine. To view the Pfizer press release, click here.

These data, presented at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting in June, further demonstrate the clinical benefit of IBRANCE® (palbociclib) as initial therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer. The PALOMA-2 study showed the combination of IBRANCE and letrozole (Femara) extended progression-free survival (PFS), or the amount of time before tumor growth, by more than 10 months compared with letrozole plus placebo. Further, the study demonstrated that the median PFS of the IBRANCE and letrozole combination exceeded two years – making it the first and only treatment for this population of women to do so in a randomized Phase 3 study.1

8 Replies

  • After 3 mos. on Ibrance and Femara my original tumor shrunk by 1/2 (as per the PET/CT scan). After 6 mos the cancer cells are not active. I am thrilled.

  • Awesome!!!

  • Fantastic news Glad to hear it I believe that others in this community will benefit from hearing your story

  • Thank you.

  • Yes, thank you. That validates why my oncologist has not given up on the drug. Seems that he is fighting for me. We have only had one 3 month follow up since I began letrozole and Ibrance. That scan did not conclusively indicate any shrinkage or stabilization to the bone mets. My next pet/ct will be December. I am looking for better news then.

  • Crossing my fingers for you Here's hoping for great scans.

  • I am on ibrance with exemestane and so far very little side effects.

  • Thanks, this mirrors my experience. 19 months in, tumor shrinking, bone Mets gone.

You may also like...